Nrx pharmaceuticals, inc. (nasdaq:nrxp) advances relationship with anson funds with $8.9 million financing, including above the market equity and senior secured debt

This financing is expected to support filing of new drug applications for nrx-100 (ketamine) and nrx-101, and to support launch of hope therapeutics investment consists of $3.5 million in above the market equity and $5.4 million in senior secured notes; expected to fund current operations into 2026 wilmington, del. , jan. 28, 2025 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx", "nrx pharmaceuticals" or the "company"), a clinical-stage biopharmaceutical company, today announced that it has entered into a binding agreement for a registered direct offering of its common stock with expected gross proceeds of $3.5 million (the "financing") with certain institutional investors.
NRXP Ratings Summary
NRXP Quant Ranking